Based on the key measurements obtained from ArriVent BioPharma,'s financial statements, ArriVent BioPharma, Common is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, ArriVent BioPharma,'s Other Current Liabilities is relatively stable compared to the past year. As of 03/26/2025, Cash is likely to grow to about 117 M, while Total Stockholder Equity is likely to drop slightly above 171.8 M. Key indicators impacting ArriVent BioPharma,'s financial strength include:
Investors should never underestimate ArriVent BioPharma,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor ArriVent BioPharma,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in ArriVent BioPharma, Common.
Net Income
(76.06 Million)
ArriVent
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Net Income Per Share
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Ev To Operating Cash Flow
Pe Ratio
Ev To Free Cash Flow
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Roe
Return On Tangible Assets
Earnings Yield
Price Earnings Ratio
Price Book Value Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Company Equity Multiplier
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Fair Value
Return On Assets
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Net Working Capital
Short Long Term Debt Total
Short Term Debt
Selling General Administrative
Other Operating Expenses
Operating Income
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Net Interest Income
Interest Income
Net Income From Continuing Ops
Probability Of Bankruptcy
Understanding current and past ArriVent BioPharma, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ArriVent BioPharma,'s financial statements are interrelated, with each one affecting the others. For example, an increase in ArriVent BioPharma,'s assets may result in an increase in income on the income statement.
ArriVent BioPharma, competes with National Vision, GMS, Yoshitsu, Gap,, and Enersys. ArriVent BioPharma, is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining ArriVent BioPharma,'s current stock value. Our valuation model uses many indicators to compare ArriVent BioPharma, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ArriVent BioPharma, competition to find correlations between indicators driving ArriVent BioPharma,'s intrinsic value. More Info.
ArriVent BioPharma, Common is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, ArriVent BioPharma,'s Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ArriVent BioPharma, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
ArriVent BioPharma, Systematic Risk
ArriVent BioPharma,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ArriVent BioPharma, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on ArriVent BioPharma, correlated with the market. If Beta is less than 0 ArriVent BioPharma, generally moves in the opposite direction as compared to the market. If ArriVent BioPharma, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ArriVent BioPharma, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ArriVent BioPharma, is generally in the same direction as the market. If Beta > 1 ArriVent BioPharma, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ArriVent BioPharma, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ArriVent BioPharma,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ArriVent BioPharma, growth as a starting point in their analysis.
ArriVent BioPharma, March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ArriVent BioPharma, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ArriVent BioPharma, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of ArriVent BioPharma, Common based on widely used predictive technical indicators. In general, we focus on analyzing ArriVent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ArriVent BioPharma,'s daily price indicators and compare them against related drivers.
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.